Body Mass Index Increase, Serum Leptin, Adiponectin, Neuropeptide Y and Lipid Levels during Treatment with Olanzapine and Haloperidol
Carregando...
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
GEORG THIEME VERLAG KG
Autores
Citação
PHARMACOPSYCHIATRY, v.44, n.5, p.169-172, 2011
Resumo
Introduction: Body mass index (BMI) increase is an undesired effect associated with antipsychotics, and crucial for patients' global health and treatment compliance. We aimed to investigate the relation between BMI during olanzapine or halopericlol treatments and leptin, neuropeptide Y (NPY), adiponectin and lipid serum levels. Methods: In this 9-month, randomized and naturalist study, 34 male patients, 18 on olanzapine and 16 on haloperidol group were enrolled, all were under monotherapy. Patient outcome was evaluated with positive and negative syndrome scale (PANSS) at every 3-month period. In each visit, BMI, leptin, NPY, lipid, olanzapine or haloperidol levels were also monitored. Results and Discussion: Leptin levels positively correlated with BMI in olanzapine (r = 0.64, p < 0.001) and haloperidol (r = 0.73, p < 0.001) groups; only in olanzapine patients, the former also correlated with PANSS score (r = 0.54, p < 0.05). NPY levels negatively correlated with olanzapine levels (r = -0.65, p < 0.01). Adiponectin levels had not significantly varied. Conclusion: Antipsychotics probably interfere on leptin and NPY signalling ways and disturb these hormones in eating behaviour control.
Palavras-chave
antipsychotic drugs, adverse effects, leptin, neuropeptide Y, adiponectin, body mass index
Referências
- American Psychiatric Association, 1994, DIAGN STAT MAN MENT
- Monteleone P, 2009, PSYCHIAT CLIN N AM, V32, P775, DOI 10.1016/j.psc.2009.08.003
- Kraus T, 1999, AM J PSYCHIAT, V156, P312
- Morimoto T, 1999, PHYSIOL BEHAV, V67, P679, DOI 10.1016/S0031-9384(99)00123-7
- Baptista T, 2000, PHARMACOPSYCHIATRY, V33, P81, DOI 10.1055/s-2000-8451
- Meguid MM, 2000, NUTRITION, V16, P843, DOI 10.1016/S0899-9007(00)00449-4
- Leibowitz SF, 1998, BIOL PSYCHIAT, V44, P851, DOI 10.1016/S0006-3223(98)00186-3
- Olesen OV, 1998, J CHROMATOGR B, V714, P309, DOI 10.1016/S0378-4347(98)00205-9
- Chaggar PS, 2011, J CLIN PHARMACOL, V51, P631, DOI 10.1177/0091270010368678
- Mukherjee S, 1996, COMPR PSYCHIAT, V37, P68, DOI 10.1016/S0010-440X(96)90054-1
- Marquina D, 2011, INT CLIN PSYCHOPHARM, V26, P169, DOI 10.1097/YIC.0b013e328342ce47
- Naslund E, 2007, PHYSIOL BEHAV, V92, P256, DOI 10.1016/j.physbeh.2007.05.017
- Kluge M, 2009, PSYCHONEUROENDOCRINO, V34, P118, DOI 10.1016/j.psyneuen.2008.08.016
- Wirshing DA, 1999, J CLIN PSYCHIAT, V60, P358
- Reynolds GP, 2010, PHARMACOL THERAPEUT, V125, P169, DOI 10.1016/j.pharmthera.2009.10.010
- Valassi E, 2008, NUTR METAB CARDIOVAS, V18, P158, DOI 10.1016/j.numecd.2007.06.004
- de Leon J, 2007, SCHIZOPHR RES, V92, P95, DOI 10.1016/j.schres.2007.01.015
- Parsons B, 2009, SCHIZOPHR RES, V110, P103, DOI 10.1016/j.schres.2008.09.025
- Jin H, 2008, SCHIZOPHR RES, V100, P70, DOI 10.1016/j.schres.2007.11.026
- BERNSTEIN JG, 1987, ANN NY ACAD SCI, V499, P203, DOI 10.1111/j.1749-6632.1987.tb36212.x
- Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503
- Dryden S, 1999, HORM METAB RES, V31, P363, DOI 10.1055/s-2007-978755
- Esen-Danac A, 2008, PROG NEURO-PSYCHOPH, V32, P1434, DOI 10.1016/j.pnpbp.2008.03.015
- FOUTAINE RJ, 2010, OBESITY, V18, P1646
- KAY S R, 1989, British Journal of Psychiatry, V155, P59
- Kim BJ, 2008, J KOREAN MED SCI, V23, P685, DOI 10.3346/jkms.2008.23.4.685
- KNOX JM, 1980, BRIT J PSYCHIAT, V136, P287, DOI 10.1192/bjp.136.3.287
- KOLAKOWSKA T, 1987, INT CLIN PSYCHOPHARM, V2, P83, DOI 10.1097/00004850-198701000-00008
- Melkersson KI, 2000, J CLIN PSYCHIAT, V61, P742
- ROTATORI AF, 1980, PSYCHOL REP, V46, P483
- Ugur T, 2008, OBESITY FACTS, V1, P103, DOI 10.1159/000122763